KineMed Inc. (www.kinemed.com) today announced a non‐ exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMed’s Dynamic Proteomics (TM) technology platform to map the impact of potential drug candidates on specific metabolic pathways.

Diabetes is an increasingly challenging global healthcare problem and in the United States affects over one quarter of Americans over the age of 65. Diabetes is a major cause of heart disease and stroke and is now also the leading cause of kidney failure, non‐traumatic lower‐limb amputations, and new cases of blindness among adults in the United States.  

Despite over 50 years of drug research, over 60% of patients remain unresponsive to current therapies, requiring novel approaches to address fundamental metabolic processes in diabetes.

Dr Scott Turner, Executive Vice‐President, R&D at KineMed, said “We are delighted to be collaborating with another of our clients in taking novel and innovative approaches by targeting disease pathways that previously remained undeveloped as drug targets, while seeking to translationally accelerate and   rapidly de‐risk the advancement of novel compounds in pre‐clinical and clinical trials.  

About KineMed, Inc.

KineMed, based in California, is the world‐leader in measuring dynamic biochemical processes that cause disease. Collaboration with KineMed offers deep expertise and access to technologic inventions that accelerate and lower the cost of drug R&D, enable new disease‐modifying therapies and diagnose and monitor patients.

The ability to monitor and control the dynamic behavior of networks, rather than isolated targets, is the next great challenge in therapeutics.  KineMed’s patented mass spectrometric technologies measure molecular fluxes in living tissues through the complex molecular and cellular networks that are responsible for disease.  

KineMed’s innovations have pioneered new fields, including Network Dynamics and In Situ Kinetic Histochemistry. Measuring changes in the dynamics of hundreds of proteins, for example, enables diagnosis and monitoring of cardiovascular, neurodegenerative, metabolic and other disorders from a drop of blood. Displaying spatial organization of metabolic fluxes in histopathologic specimens provides functional signatures of disease.

KineMed’s established programs with premier pharmaceutical collaborators address critical challenges facing drug discovery:

• Focus on causes rather than symptoms: Generating pivotal knowledge for developing blockbuster drugs, by targeting underlying biochemical causes
• Systems biology approach: Insight into intact living systems, rather than simplified models, ensures that drug effects are understood in their intended biological context 
• Reduce late‐stage attrition: Early, decision‐relevant metrics of drug activity separate winners from losers and reduce later failures to improve the NPV of R&D spend
• Powerful assays of disease state: Custom‐developed assays create companion diagnostic tests for personalized medicine

KineMed is seeking broad collaborations with pharma, CRO, histopathology, diagnostics, medical instruments and biotech partners.

KineMed Inc. 
Lila Taylor, Director of Business Development 
510-655-6525 ext. 141 
[email protected]